Page 41 - CIBERES2016-ENG

Most relevant scientific articles
• Hoeper M.M., McLaughlin V.V., Barbera J.A., Frost A.E., Ghofrani H.-A., Peacock A.J. et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. The Lancet Respiratory Medicine. 2016;4(11):894-901.
• Delcroix M., Lang I., Pepke-Zaba J., Jansa P., D’Armini A.M., Snijder R. et. al. Long-Term Outcome of Patients with Chronic Thromboembolic Pulmonary Hypertension: Results from an International Prospective Registry. Circulation. 2016;133(9):859-871.
• Watz H., Tetzlaff K., Wouters E.F.M., Kirsten A., Magnussen H., Rodriguez-Roisin R. et. al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: A post-hoc analysis of the WISDOM trial. The Lancet Respiratory Medicine. 2016;4(5):390-398.
• Ambrosino N., Vitacca M., Dreher M., Isetta V., Montserrat J.M., Tonia T. et. al. Tele-monitoring of ventilator-dependent patients: A European Respiratory Society Statement. European Respiratory Journal. 2016;48(3):648-663.
• Scioscia G., Blanco I., Arismendi E., Burgos F., Gistau C., Barbaro M.P.F. et al. Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. Thorax. 2016.
Highlights
• Participation in the European Reference Network on Rare Respiratory Diseases (ERN-LUNG), Pulmonary Hypertension
• Participation in the ERS / ATS Task Force for the standardization of measurement of carbon monoxide diffusion capacity (F. Burgos).
• Participation in Task Forces of the European Respiratory Society (ERS): Pulmonary Hemodynamics During Exercise (J.A. Barberà); Exercise Training and Rehabilitation in Patients with Severe Chronic Pulmonary Hypertension (I. Blanco, J.A. Barberà).
• Participation in the International Consortium for Genetic Studies in Pulmonary Arterial Hypertension (PAH).
• Development of the project: Network Management of Patients with Rare Diseases: Pulmonary Hypertension as a use case (GERAR) within the RETOS Program of the Ministry of Economy, Industry and Competitiveness.
RES
research groups 41